Page 19 - Flipbook

1L, first-line; ADC, antibody-drug conjugate; atezo, atezolizumab; BSC, best supportive care; EV, enfortumab vedotin; chemo, che
Different treatment strategies impacting 1L SoC in the

near future

Metastatic UC
Metastatic UC Metastatic UC
CR / PR / SD following
platinum-based treatment Cisplatin eligible / ineligible Cisplatin eligible / ineligible

R R R

Placebo IO + IO + IO
IO IO Chemo IO Chemo
/ BSC chemo or ADC

JB100 avelumab BSC OS KN361 pembro pembro + chemo chemo OS, PFS DANUBE durva durva + treme chemo OS
[NCT02603432] [NCT02853305] [NCT02516241]

HOOSIER pembro placebo 6-mo CM901 -- nivo + chemo* chemo OS, PFS CM901 -- nivo + ipi chemo OS,
[NCT02500121] PFS [NCT03036098] [NCT03036098] PFS

IMvigor130 atezo atezo + chemo chemo OS, PFS, EV-302 pembro + EV + OS,
[NCT02807636] safety [NCT04223856] pembro chemo chemo PFS

*For cisplatin-eligible patients only.